SCHEMBL30746561

SCHEMBL30746561

Cc1ccc(S(=O)(=O)N/N=C\c2cncc(Nc3ccc(Br)cc3F)c2C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.54
▸ MAPT P10636 5/20 0.54
▸ RBM39 Q14498 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ KMT2A Q03164 8/20 0.43
▸ MEN1 O00255 6/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ POLB P06746 3/20 0.43
▸ ALOX12 P18054 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ RECQL P46063 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ KCNA5 P22460 2/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26994271 1.00 ALDH1A1 (0.54) ALDH1A1MAPTRBM39SMN1; SMN2KMT2A
SCHEMBL26985012 0.89 ALDH1A1 (0.47) ALDH1A1MAPTRBM39SMN1; SMN2KMT2A
SCHEMBL30746537 0.89 ALDH1A1 (0.47) ALDH1A1MAPTRBM39SMN1; SMN2KMT2A
SCHEMBL30746641 0.81 ALDH1A1 (0.47) ALDH1A1MAPTRBM39SMN1; SMN2KMT2A
SCHEMBL26984983 0.81 ALDH1A1 (0.47) ALDH1A1MAPTRBM39SMN1; SMN2KMT2A
SCHEMBL26985292 0.77 TP53 (0.40) MAPTKMT2ALMNAGAAL3MBTL1
SCHEMBL30746459 0.77 TP53 (0.40) MAPTKMT2ALMNAGAAL3MBTL1
SCHEMBL34463286 0.74 ALDH1A1 (0.58) ALDH1A1MAPTRBM39SMN1; SMN2KMT2A
SCHEMBL30746472 0.72 ALDH1A1 (0.48) ALDH1A1MAPTRBM39SMN1; SMN2KMT2A
SCHEMBL26985182 0.72 ALDH1A1 (0.48) ALDH1A1MAPTRBM39SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
EP-4551558-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS Nested Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 ALDH1A1 2176/4885MAPT 4493/4885RBM39 4784/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 ALDH1A1 3364/4885MAPT 1741/4885RBM39 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback